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                            Received May 29, 1972 
      Methyl N,N'-diacetyl kasugaminide (21)and its C-4 epimer (24) were synthesized starting 
  from D-glucose. (21) was converted to N,N'-diacetyl-l-chlorokasugamine (28). Konigs-Knorr 
  reaction of the chloride with 1,2;5,6-di-O-isopropylidene-DL-chiro-inositol (35) provided the 
  derivative of kasuganobiosamine (36) and its diastereomer (40). Kasuganobiosamine analog 
  having allo-inositol in place of D-chiro-inositol moiety was also synthesized. The biological 
  activity against P. oryzae was examined after introduction of carboxyformimidoyl group to 
  kasuganobiosamine and its related compounds. 
                          INTRODUCTION 
   Kasugamycin was discovered by Umezawa and his associates" in the cultured 
broth of Streptornyces kasugaensis isolated from the soil of Kasuga Taisha in Nara 
prefecture. The configuration was elucidated to be D-3-O-[2-amino-4-(1-carboxyfor-
mimidoyl)-amino-2,3,4,6-tetradeoxy-a-D-arabino-hexopyranosyl]-chiro-inositol (1) by 
degradation into componentsz' and by physical methods such as PMR spectra and x-ray 
analysis.3' Kasugamycin is now widely used as an excellent fungicide against rice blast 
caused by Piricu/aria oryzae4' owing to its high selectivity and low toxicities to animals') 
and fishes.6' Therapeutic uses against diseases due to Pseudornonas," Staphylococcus') 
and Bacillus') are also reported. 








NH O OH 
                             II II                 I R = -C-C-OH 
                    2 R = H
   Kasugamycin is classified as a basic oligosaccharide antibiotic107 having an 
aminosugar moiety linked with a cyclitol or an aminocyclitol as an aglycone, in common 
with streptomycin, kanamycins, gentamicins, neomycins and so on. These antibiotics 
are known to exhibit their antimicrobial activities as a result of inhibition of protein 
synthetic system on 30S-ribosomal fraction.' There exists a certain difference on their 
 41117f i i) i : Department of Agricultural Chemistry, College of Agricul-
  ture, Kyoto University. 
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modes of action between kasugamycin and the other aminoglycosidic antibiotics, 
that is, the former inhibits the bond formation of aminoacyl-t-RNA with messenger— 
RNA,12' while the latter compounds cause miscoding.131 The difference may be due 
to structural difference in cyclitol moiety, that is, kasugamycin contains neither 
streptamine nor deoxystreptamine moiety as its component which are thought to be 
responsible for miscoding activity.14' 
   In 1968, we synthesized kasuganobiosamine starting from D-glucose.15' In this 
paper we describe the outline of our synthetic work of kasugamycin and its related 
compounds. 
   After our publication, the following two reports were published. Suhara et al.16' 
synthesized alkyl (methyl, ethyl, isopropyl) kasugaminide and kasuganobiosamine 
starting from 6-methyl-3,4-dihydro-2H-pyran-2-one by means of addition of nitrosyl 
chloride to the olefine followed by glycosidation with the use of the Lemieux's nitroso— 
dimer method. Yasuda1 n et a!. synthesized methyl kasugaminide starting from 2— 
ethoxy-6-methyl-3,4-dihydro-2H-pyran via hydroboration to the double bond and 
substitution with chloramine of the resulting borate trimer. 
1. Synthesis of Methyl Kasugaminide 
   Frequent occurence of aminosugars as components of various natural products10,18> 
such as antibiotics, metabolites of microorganisms and animal and bacterial mucopoly-
saccharides have stimulated a number of carbohydrate chemists. The polyfunctional 
amino groups of aminosugars in these basic oligosaccharide antibiotics are thought 
to play important roles for their prominent biological activities. Thus, synthetic studies 
of this group of compounds have been carried out with enormous efforts. 
   Kasugamine (2,4-diamino-2,3,4,6-tetradeoxy-D-arabino-hexopyranose) (3) is a 
novel diaminosugar which was obtained as a methyl glycoside by methanolysis of 
kasuganobiosamine with hydrochloric acid in methanol.2> The biosynthetic studies 
elucidated that glucosamine or glucose was incorporated into kasugamine moiety 
without fragmentation.19' 
   Starting from D-glucose, we synthesized methyl kasugaminide and its derivatives 
via the following routes.15"> 
a) Synthesis of Methyl-2-Acetamido-2,3-Dideoxy-a-D-arabino-Hexopyranoside (13) 
and Methyl-2-Acetamido-2,3-Dideoxy-a-D-ribo-Hexopyranoside (14). 
    Methyl 4,6-O-benzylidene-2-0-p-tolylsulfonyl-a-D-glucopyranoside20' prepared 
from methyl 4,6-O-benzylidene-a-D-glucopyranoside by selective tosylation was convert-
ed to methyl 4,6-0-benzylidene-3-deoxy-a-D-arabino-hexopyranoside (4) via an epoxide 
by means of the Prins method.221> Methyl 4,6-0-benzylidene-3-deoxy-a-D-ribo-hex-
opyranoside (8) was derived by selective detosyloxylation at C-3 by LiA1H4 reduction 
of methyl 4,6-0-benzylidene-2,3-di-O-p-tolylsulfonyl-a-D-glucopyranoside according to 
the Vis and Karrer procedure.221 
   The mechanism of this selective detosyloxylation was discussed by Umezawa 
et al.23' and Zobacova et al.24' independently, that is, the ditosylate is first selectively 
reduced at C-2, and a C-2 0-aluminum hydride intermediate derived from the resultant 
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methyl-3-O p-tolylsulfonyl-a-D-glucopyranoside undergoes an intramolecular nucleo-
philic substitution at C-3 to yield (8). Similar mechanism for the action of LiA1H4 
on 6-O-benzoyl-1,2-O-isopropylidene-5-O-tosyl-a-D-glucofuranose has been described 
by Hedgley et al.25' 
   The introduction of amino group to the C-2 position was performed as follows. 
Mono-ol (8) was oxidized with dimethyl sulfoxide (DMSO), dicyclohexyl carbodi-
imide (DCCD) and pyridinium trifluoroacetate (Pfitzner-Moffat reagent)26' to give 
methyl 4,6-O-benzylidene-3-deoxy-a-D-erythro-hexopyranosid-2-ulose (11) in a crystal-
line state in 78 % yield. Oxidation of (4) under the same condition gave (11) in 70 
yield. The IR spectrum of (11) showed a peak at 1730 cm-' characteristic of six mem-
bered cyclic ketones, and the PMR spectrum showed an anomeric proton signal at 
5.42r as a singlet. Recently, Rosenthal27 obtained the same product by the use of 
DMSO-Ac20 oxidation system in 80 % yield. Williams et al.28' oxidized methyl 4,6-0— 
benzylidene-8-D-ribo-hexopyranoside with Ru04 to afford the corresponding ulose in 
70% yield. Paulsen et al.29' heated methyl 4,6-0-benzylidene-2,3-di-0-methylsulfonyl— 
a-D-allo-, —gluco—, and —altro-pyranosides with anhydrous hydrazine. Subsequent 
acetylation and removal of hydrazine function gave the ulose (11) in 53 % yield. 
   Oximation of (11) with hydroxylamine hydrochloride in the presence of sodium 
acetate yielded methyl 4,6-0-benzylidene-3-deoxy-2-oximino-a-D-erythro-hexopyra-
noside (12) as crystals in 98 % yield. (12) was hydrogenated in AcOH in the presence 
of Pt2O to give a mixture of six ninhydrin positive substances when detected on a 
thin layer chromatogram, which, without separation, was acetylated with Ac20 in 
methanol. A major product crystallized from the reaction mixture was methyl 2— 
acetamido-4,6-0-benzylidene-2,3-dideoxy-a-D-ribo-hexopyranoside (10), the con-
figuration of which was confirmed by comparing its PMR spectrum with that of its 
C-2 epimer as described later. 
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   Other reduction procedures were also attempted. LiA1H4 reduction of (12) in 
ether followed by acetylation and subsequent purification on silicic acid column 
chromatography gave the compound (10) in 73 % yield along with methyl 2-acetamido-
4,6-O-benzylidene-2,3-dideoxy-a-D-arabino-hexopyranoside (7) in 15 % yield. The 
latter was considered to have the same C-2 configuration with kasugamine. Unequivocal 
configurations of (7) and (10) were determined by means of PMR spectra in addition 
to IR spectra and elemental analysis. The PMR spectrum of (7) in deuteriochloroform 
showed an axial acetamido signal at 7.96r as a singlet and an anomeric proton signal 
at 5.48r as a doublet P1,2-0.8 Hz) corresponding to H1-H2: equatorial-equatorial, 
while (10) showed an equatorial acetamido signal at 8.03r as a singlet and an anomeric 
proton signal at 5.40r as a doublet (J1,2=3.5 Hz) corresponding to H1-H2: equatorial-
axial. These findings were well consistent with a general rule in pyranose structures 
that methyl protons of axial acetoxy or acetamido substituent resonate at a lower field 
than those of equatorial substituent,30' and that the coupling constants between adjacent 
C-1 and C-2 hydrogen atoms, notably in methyl 4,6-O-benzylidene-a-D-hexopyranosides, 
situating in axial-equatorial and equatorial-axial orientations are in the range of 
0.6-1.7 and 3.3-3.8 Hz, respectively.31' 
   It is generally accepted that reduction of a six membered cyclic ketoxime with 
catalytic hydrogenation gives an axial amino group, while reduction with sodium 
amalgam gives equatorial one predominantly.32' Reduction of (12) with sodium 
amalgam was unsuccessful because of its very low solubility in solvents such as water, 
ethanol and dioxane. Catalytic hydrogenation as well as LiAIH4 reduction of (12) 
afforded (10) having the equatorial amino group, predominantly. Thus, the above 
empirical rule would hold only for sterically unhindered ketoximes. For rather complex 
ketoximes such as (12), hydride ion or activated catalyst should approach the C=N 
bond from the opposite side of C-1 group so that the steric hindrance is minimized. 
A similar stereoselectivity was also observed for NaBH4 reduction of (11) in N,N-
dimethyl formamide (DMF)-methanol giving (8) stereospecifically in 85 % yield without 
any detectable formation of (4). 
   Existence of syn- and anti-forms of oxime (12) as reported by Beynon et a1.33> 
for other oximes need not to be considered, since PMR spectra of stepwise purified 
samples of (12) was not varied. 
   We also tried to prepare (7) by the following methods. Methyl 4,6-O-benzylidene-
3-deoxy-2-O-p-tolylsulfonyl-a-D-ribo-hexopyranoside (9) derived from (8) was refluxed 
with NaN3 in DMF containing 10% of water, followed by purification by silica gel 
column chromatography leading to methyl 2-azido-4,6-O-benzylidene-2,3-dideoxy-a-
D-arabino-hexopyranoside (6) as a syrup. In this reaction, the tosyloxy group was 
substituted by the azido group accompanying with the Walden inversion. The IR 
spectrum of the product showed a strong absorption at 2170 cm-1 characteristic of 
the azido group. (6) was catalytically hydrogenated over Pt02 in methanol followed 
by acetylation with Ac20 in methanol to give methyl 2-acetamido-4,6-O-benzylidene-
3-deoxy-a-D-arabino-hexopyranoside (7) in 86 % yield. Methyl 4,6-O-benzylidene-3-
deoxy-2-O-p-tolylsulfonyl-a-D-arabino-hexopyranoside (5) derived from (4) did not 
give the corresponding azido derivative. 
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   The difference in reactivity between (5) and (9) against SN2 substitution would 
be assumed to arise as follows. According to Richardson,34' reactivities of  sulphonic 
esters of carbohydrate derivatives towards SN2 reaction depend on the stabilities of 
polarized transition states, which are influenced by electronegativities and steric effects 
of neighboring substituents. For example, low reactivities of C-2 sulfonates of 
aldopyranosides are well explained by additive dipolar effects caused by C-3 and C-1 
substituents containing ring oxygens. The C-2 polar bonds in the intermediate of 
a-D-anomers (15) might be highly destabilized by unfavorable alignments with nearly 
antiparallel permanent dipoles caused by C-1—O-5 and C-1—O-1 bonds, while those 
of (3-D-anomers (16) are not so destabilized since the permanent dipole moments caused 
by C-1—O-1 bonds are nearly perpendicular to the C-2 polar bonds. 




   From the Newman's projection (17) of the transition state of the substitution 
reaction of (9) by an azide ion along the C-3—C-2 bond axis, it is recognized that 
the most part of the susceptibility of (9) to the substitution reaction is undoubtedly 
owing to the absence of any polar substituents on C-3. The low reactivity of (5), 
however, having a similar transition state to (17), are not explained well by the above 
hypothesis. The bulkiness around the anomeric carbons might be operative in this case. 
   Different synthetic method of (7) has been reported. Buss et a1.35' obtained (7) 
by reductive cleavage of methyl 4,6-O-benzylidene-2,3-epiimino-a-D-mannopyranoside. 
Goodman et al.36' synthesized (7) starting from methyl 2,3-anhydro-4,6-O-benzylidene-
a-D-mannopyranoside via its benzylthio derivative. Rosenthal et al.27' derived the 
same compound by reduction of the acetate of (12). (3-D-anomer of benzamido analog 
of (10) was synthesized by Meyer zu Reckendorf and W.A. Bonner37' starting from 
methyl 4,6-O-benzylidene-(3-D-glucosaminide. 
   (7) and (10) were hydrolyzed with aqueous sulfuric acid to give methyl 2-acetamido-
2,3-dideoxy-a-D-arabino-hexopyranoside (13), and its C-2 epimer (14), respectively. 
The products were acetylated to the corresponding 4,6-di-O-acetyl derivatives. One 
of the sugar components of recently discovered aminoglycosidic antibiotic, livido-
mycin A38' has been found to be identical with (14). 
b) Synthesis of Methyl 2,4-Diacetamido-2,3,4,6-Tetradeoxy-a-D-arabino-Hexopy-
ranoside (Methyl N,N'-di-acetyl-a-kasugaminide) (21) and Methyl 2,4-Diacetamido-
2,3,4,6-Tetradeoxy-a-D-lyxo-Hexopyranoside (24). 
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   (13) was selectively tosylated at primary hydroxyl group by treatment with 1.3 
molar equivalent of' tosyl chloride in pyridine followed by addition of Ac20 to yield 
methyl 2-acetamido-4-O-acetyl-2,3-dideoxy-6-O-p - tolylsulfonyl - a - D -arabino - hexopy-
ranoside (18) in 57 % yield. The structure of (18) was confirmed by the PMR and IR 
spectra. (18) was heated with sodium iodide in a sealed tube to afford methyl 
2-acetamido-2-O-acetyl-6-iodo-2,3,6-trideoxy-a-D-arabino-hexopyranoside (19) as a pale 
yellow syrup, its PMR and IR spectra being consistent with the postulated structure. 
The catalytic hydrogenation of (19) over Raney Ni in the presence of Amberlite IR-45 
(OH- form) in methanol followed by deacetylation with sodium methoxide in methanol 
gave methyl 2-acetamido-2,3,6-trideoxy-a-D-arabino-hexopyranoside (20). The PMR 
spectrum of (20) showed a doublet (J5,6=6.8 Hz) at the highest field corresponding 
to 3 protons indicating the presence of C-5 methyl group. 
RI CH2CH3CH3 
        R----0\0 
AcNAcNHR= AcN 
Rz OCH3OCH3OCH3 
         18 RI= OTs R2 = OAc 22 R = OH 25 R = 0 
19 RI= I R2 = OAc 23 R = OMs 26 R = NOH 
        20 RI= H R2 =OH 24 R = NHAc 
         21 RI= H R2 =NHAc 
   Introduction of amino group into C-4 position was performed as illustrated below. 
The chromic acid oxidation of (20) gave methyl 2-acetamido-2,3,6-trideoxy-a-a-
threo-hexopyranosid-4-ulose (25). The IR spectrum of the product showed a strong 
absorption at 1730 cm-1 characteristic of six membered cyclic ketone. (25) was treated 
with hydroxylamine hydrochloride in the presence of sodium acetate in aqueous ethanol 
to afford methyl 2-acetamido-4-oximino-2,3,4,6-tetradeoxy-a-D-threo-hexopyranoside 
(26). The structure was confirmed by elemental analysis and IR spectrum. (26) was 
catalytically hydrogenated over platinum oxide in methanol to give methyl 2-acetamido-
4-amino-2,3,4,6-tetradeoxy-a-D-lyxo-hexopyranoside which, without isolation, was 
acetylated to methyl 2,4-diacetamido-2,3,4,6-tetradeoxy-a-D-lyxo-hexopyranoside (24). 
Its structure was unambiguously ascertained by the PMR spectrum. Thus, the C-4 
epimer of the kasugamine derivative was obtained by this procedure. 
   Catalytic hydrogenation of (25) over platinum oxide followed by chromatographic 
separation gave methyl 2-acetamido-2,3,6-trideoxy-a-D-/yxo-hexopyranoside (22) 
having an axial hydroxyl group on C-4 in 57 % and (20) in 20 % yield, respectively. 
Inversion of the configuration of C-4 of (20) via the corresponding sulfonate was 
unsuccessful because of an unstability of the sulfonate. (22) was mesylated with methyl 
chloride in pyridine followed by chromatographic purification over silicic acid to 
afford methyl 2-acetamido-2,3,6-trideoxy-4-O-methylsulfonyl-a-D-lyxo-hexopyranoside 
(23) as a syrup, which, without further purification, was refluxecl with NaN3 in DMF 
to yield corresponding azido derivative, methyl 2-acetamido-4-azido-2,3,4,6-tetradeoxy-
                             (280)
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 a-D-arabino-hexopyranoside. The spectrum of the product showed a sharp absorption 
band at 2140 cm-' characteristic of the azido group. The azide was hydrogenated in 
methanol in the presence of platinum catalyst and followed by acetylation to give 
methyl 2,4-diacetamido-2,3,4,6-tetradeoxy-a-D-arabino-hexopyranoside (21), mp 194.5-
196 °, [a]v +100' (c=1.0, H2O). The overall yield of (21) from (23) was 16 %. As 
shown in Fig. ' 1, the PMR spectrum of (21) in D2O showed two acetamido signals 
at 8.02r and 7.97r, and an anomeric proton signal at 5.40r (1H, d., J1,2=1.5 Hz, 
corresponding to 1,2-diaxial structure). 
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                  Fig. 1. PMR spectrum of (21) in D20 at 60 MHz. 
   Substitution reaction at C-4 of sugars in DMF, DMSO, HMPA, methyl cellosolve 
and acetone is known to proceed in SN2 mechanism.39> Thus, the structure of (21) 
was reasonably considered as methyl N,N'-diacetyl-a-kasugaminide. The authentic 
sample derived from kasuganobiosamine by methanolysis was identical with (21) 
in all respects of IR and PMR spectra, specific rotatory power and melting point. 
II. Synthesis of Kasuganobiosamine and Its Related Compounds 
   Kasuganobiosamine having the structure, D-3-0-(2,4-diamino-2,3,4,6-tetradeoxy— 
a-D-arabino-hexopyranosyl)-chiro-inositol (2) was obtained by alkaline hydrolysis of 
kasugamycin. The a-glycosidic Iinkage is characteristic of all known aminoglycosidic 
antibiotics, and seem to be indispensable for the antibiotic activity. The development 
of synthetic methods of biological significant a-glycosides has been a fascinating subject 
for carbohydrate chemists. 
   Among a number of glycosidation methods,40--43) the Konigs-Knorr reaction is 
most frequently employed with complex secondary alcohols as aglycons. In this method, 
the reaction of glycosyl halides having an acyl or other potentially participating groups 
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at C-2 occurs to give glycosides where the  C-1 and C-2 substituents are in the trans 
relationship via an acyloxonium or analogous intermediates. The Konigs-Knorr 
reaction using 2-aminoacylhalides is more complex than that of 2-acyloxyhalides, 
since the former are apt to form oxazolines or oxazolidines which prevent aglycones 
from nucleophilic attack on the anomeric center resulting in poor yields. 2-Aminoacyl 
halides are unstable with moisture causing an N-O migration which occurs more 
remarkably with 1-bromo-derivatives than 1-chloro-derivatives. We used N,N'-diacetyl-
1-chloro-kasugamine (28) to synthesize kasuganobiosamine by a modified Konigs-
Knorr reaction, since the a-glycosidic linkage formation was expected predominantly 
owing to the neighboring participation of the C-2 axial acetamido group. 
a) Synthesis of N,N'-Diacetyl-1-chloro-Kasugamine (Acetochlorokasugamine) (28). 
   6N-formic acid hydrolysis of (21) at 60 ° and the following acetylation and purifi-
cation on a column of silicic acid yielded triacetyl kasugamine (27) as a syrup in 40 
yield and 30 % of the starting material was recovered. From the PMR spectrum, (27) 
was found to be an almost equimolar mixture of anomers. Since they were not separable 
by column chromatography, the next reaction was performed without separation of 
anomers. Aqueous hydrochloric acid hydrolysis of (21) followed by acetylation gave 
a pyrrolidine sugar (29), which was identified by IR spectrum showing that the first 
amide absorption was stronger than the second amide absorption. 
       CH3CH3 
             0Ac0- NAc 
            AcN RAcH N Ac 
              AcHN 
          27 R= OAc
29                   28 R= CI 
   By treatment of (27) with HCI-AcOH-CHC13 at 30°C, N,N'-diacetyl-l-chloro-
kasugamine (28) was precipitated as a hygroscopic amorphous solid, which was used 
for the condensation reaction after a few washings with dry ether and the following 
desiccation over pottasium hydroxide. (28) may convert with moisture to 4-acetamido-
1-O-acetyl-2-amino-2,3,4,6-tetradeoxy-D-arabino-hexopyranose hydrochloride so that 
an anhydrous condition should be maintained in the reaction course. 
b) Synthesis of 1,2;5,6-Di-O-Isopropylidene-DL-chiro-Inositol (35). 
   Out of eight possible stereoisomers of inositol, only chiro-inositol (1,2,4/3,5,6) 
(33) can be resolved to antipodes. They are present in nature in the form of monomethyl 
ether and phosphoric ester.44' For the total synthesis of kasugamycin, it is necessary 
to synthesize D- or DL-chiro-inositol, but D-chiro-inositol has never been synthesized. 
   We have explored convenient synthetic methods45> of inositol starting from cis-
and trans-benzeneglycol, (30) and (31). Conduritol-F(32) derived from cis-benzeneglycol 
(30) via 1,2-anhydroconduritol-E was cis-hydroxylated with pottasium permanganate 
to give (33) in 69 % yield. Trans-hydroxylation of conduritol-A,B and E via epoxidation 
(2B2)
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with perbenzoic acid and the following acid cleavage of the resulting epoxide gave (33). 
Different route to prepare DL-chiro-inositol reported by Angyal et a/.46t was also 
employed with a little modification. A number of synthetic route of DL-chiro-inositol 
other than that described above have also been reported.44' (33) was triacetonated with 
2,2-dimethoxypropane in DMF in the presence of catalytic amount of p-toluenesulfonic 
acid to afford 1,2;3,4;5,6-tri-O-isopropylidene-DL-chiro-inositol (34). Selective hydrolysis 
of the trans-isopropylidene group of (34) with AcOH-I-120-CHC13 gave 1,2;5,6-di-O— 
isopropylidene-DL-chiro-inositol (35). The IR spectrum of (35) in nujol mull was 
different from that of the corresponding optical active derivative, indicating that (35) 
may exist as a racemate. (35) was used for the aglycone of the glycosidation reaction 
without resolution to its antipodes. The hydroxyl groups on C-3 and C-4 of (35) 
are equivalent to each other as far as the monoglycoside formation is concerned. 
   From the biosynthetic studies, it has been proved that myo-inositol, but not D-
chiro-inositol, was incorporated into D-chiro-inositol moiety of kasugamycin.47 
c) Glycosidation by Konigs-Knorr Reaction. 
   The condensation reaction of acetochlorokasugamine (28) with (35) was carried 
out as follows. (28) and (35) were stirred at 25-30°C for a week in anhydrous chloro-
form in the presence of Ag2CO3i AgC1O4 and drierite in dark. The purification of the 
reaction mixture on a column of silicic acid yielded condensation product showing 
a single spot on TLC. Its IR and PMR spectra indicated the presence of hydroxyl, 
acetamido and isopropylidene groups. After trimethylsilylation, gas chromatography 
showed two peaks, indicating that the condensation product consists of two compounds. 
Careful column chromatography of the condensation product over silicic acid gave 
the crystalline solid (A) from the faster eluating fractions, while the pure amorphous 
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compound (B) was obtained from the slower eluating fractions. The compound A 
was identical with the authentic sample of  N,N'-diacetyl-1',2'; 5',6'-di-O-isopropylidene 
kasuganobiosamine (36) derived from N,N'-diacetyl kasuganobiosamine by treatment 
with 2,2-dimethoxypropane in DMF in the presence of p-toluenesulfonic acid. The 
molecular weight of the acetyl derivatives of compound A and B was determined to 
be 514 by mass spectroscopy. Acid hydrolysis of the compound B with 6N-hydrochloric 
acid and the following acetylation afforded hexa-O-acetyl-L-chiri-inositol which was 
identified unequivocally by the comparison with naturally occurring L-chiro-inositol 
derivatives. Thus, it should be concluded that compound B was L-1,2 ;5,6-di-O-isopro-
pylidene-3- O-(2,4-diacetamid o-2, 3,4, 6-tetradeoxy-a-D-arabino-hexopyrano syl)-ch iro— 
inositol (40), a diastereomer of compound A. The structures were confirmed by their 
PMR spectra in CDC13 as shown in Fig. 2, and Fig. 3. 
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                Fig. 3. PMR spectrum of (40) in CDC13 at 60 MHz. 
   (36) and (40) were hydrolyzed with saturated barium hydroxide to yield (38) and 
(41), which were lead to the corresponding hydrochlorides (39) and (42). (36) and (40) 
were deacetonated with aqueous acetic acid followed by acetylation to give heptaacetyl 
kasuganobiosamine (43) and its diastereomer (46), respectively. By Ba(OH)2 hydrolysis, 
(43) and (46) were converted to the corresponding diamines (44) and (47) which were 
further lead to hydrochlorides (45) and (48), respectively. 
   Condensation reactions of acylhalogeno sugars with inositol derivatives have 
been reported. For example, Angyal el al.48' condensed acetobromomannose with 
DL-1,4,5,6-tetra-O-acetyl-myo-inositol to afford the corresponding condensation product 
in 4.5 % the yield. Caldwell and Anderson491 condensed aceto-bromo (or-iodo) glucose 
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with 1,2;5,6-di-O-isopropylidene-3-O-methyl-D-chiro-inositol to afford D-1,2;5,6-di-O— 
isopropylidene-3-O-methyl-4-O-(tetra-O-acetyi-(3-D-glucopyranosyl)-chiro-inositol in 
56% yield. 
d) Synthesis of D-1,2;5,6-di-O-isopropylidene-4-O-(2,4-diacetamido-2,3,4,6-tetrad-
eoxy-a-D-arabino-hexopyranosyl)-allo-inositol (50). 
   Quite a few kasugamycin analogs have been synthesized to examine the structure— 
activity relationship. Since the most interests have been forcused upon modification 
of the carboxyformimidoyl function, but not upon those of the inositol moiety, we 
tried to synthesize the analogs where D-chiro-inositol moiety is changed to allo-inositol. 
   Treatment of (36) with methanesulfonyl chloride in pyridine gave D-1,2;5,6-di-O— 
isopropylidene-3-O-(2,4-diacetamido-2, 3, 4, 6-tetradeoxy-a-D-arabino-hexopyranosyl)— 
O-methylsulfonyl-chiro-inositol (37). PMR spectrum of (37) in CDC13 showed the 
existence of methylsulfonyl function at 6.80r instead of the hydroxyl proton. (37) 
was refiuxed with sodium acetate in DMF containing 0.5 % water for 70 hrs. to give 
D-3-O-acetyl-1, 2; 5, 6-di-O-isopropylidene-4-O-(2,4-diacetamido-2, 3, 4, 6-tetradeoxy-a— 
D-arabino-hexopyranosyl)-allo-inositol (49) in an amorphous state in 26% yield. 
D-1, 2 ; 5, 6-di-O-isopropylidene-4- O-(2, 4-diacetamido-2, 3,4, 6-tetradeoxy-a-n-arabino— 
hexopyransyl)-allo-inositol (50) was also formed as crystals in 49 % yield by the 
hydrolysis of (49) in the course of the reaction. The structure of (50) was ascertained 
   CH3CH3 
0-----0 
    RINHRNH\ 
  RI NHRNH 
CH3 
          0 OR
2 0 CH30 OR OR       OQ--- OR 
Ox0OR OR 
                 H3C CH3 
     49 Ri=R2=Ac53 R Ac 
       50 RI = Ac R2= H54 R=H
        5 I Ri = R2 = H55 HC1.salt of 54 
         52 HCl salt of 51 
by comparing its PMR spectrum (Fig. 4) with that of the starting material (36) (Fig. 
2). A marked difference between (36) and (50) was observed in the signals of isopropyli-
dene and acetamido protons. That is, (36) showed isopropylidene signals at 8.64r 
(s., 6H) and 8.50r (s., 6H), and acetamido signal at 8.00r (s., 6H), while (50) showed 
isopropylidene sigaals at 8.64r (s., 6H), 8.53r (s., 3H) and 8.47r (s., 3H), and acetamido 
signals at 8.00r (s., 3H) and 7.82r (s., 3H). 
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                     Fig. 4. PMR spectrum of (50) in CDCI3 at 60 MHz. 
      The acid hydrolysis of (50) with 6N-HC1 and subsequent acetylation gave hexa-O— 
   acetyl-allo-inositol together with pyrrolidine sugars, supporting the, structure of (50). 
   Deacylation of (50) with Ba(OH)2 gave the corresponding diamine (51), which was 
   treated with aqueous hydrochloric acid to lead to hydrochloride (52). Deacetonation 
   of (50) and the following acetylation gave L-2,3,4,5,6-penta-O-acetyl-1-O-(2,4— 
   diacetamido-2,3,4,6-tetradeoxy-a-D-arabino-hexopyranosyl)-allo-inositol (53) which was 
   deacetylated with aqueous barium hydroxide to give the diamino-derivative (54) and 
   the corresponding hydrochloride (55). 
      (51), (52), (54) and (55) were subjected to the bioassay after introduction of the 
   carboxyformimidoyl group. 
III. Synthesis of Kasugamycin (1) and Related Compounds (56), (57) 
      There are a number of natural and synthetic amidines exhibiting biological 
activities50' which are used as medicines and agricultural chemicals, but nothing but 
   kasugamycin has been reported having carboxyformimidoylamino (or oxalamidino) 
   group. Carboxyformimidoyl group has been thought to play an important role for 
   the biological activity. For example, kasuganobiosamine itself is inactive, while methyl 
   deinositol kasugamycin (methyl 2-amino-4-carboxyformimidoylamino-2,3,4,6— 
   tetradeoxy-u-arabino-hexopyranoside) is known to have a very weak but definite 
   activity against P. oryzae.51 The C-4 oxamide derivative of kasuganobiosamine has 
   been found to exhibit a low activity, 6 % of that of kasugamycin, against P. oryzae.52> 
   Cron et a1.53' has synthesized a number of C-4 aliphatic amidino analogs by semi— 
   synthetic procedures. Among them, C-4 acetamidino derivative was found to have 
   about two times stronger biological activity than kasugamycin, although its 
   antimicrobial spectrum is different from that of kasugamycin. Suhara et al.54> has 
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                  Fig. 5. Introduction of Carboxyformimidoyl Group. 
reported that the C-4 guanidine analog of kasugamycin derived by the modification 
of carboxyformimidoyl-amino group exhibits 50-100 times stronger antibacterial 
activity against gram negative bacteria than kasugamycin. 
   The method of introduction of carboxyformimidoyl group into the C-4 amino 
function was developed by Umezawa2> as shown in Fig. 5. The method is the selective 
introduction of ethyl oxalodiimidyl group into C-4 amino function followed by mild 
acid hydrolysis to give kasugamycin. However, the yield was not clearly determined. 
Alternate procedure has been reported by Cron et a1..53, The protection of the C-2 
amino function of kasugamycin with dimedone and the following removal of the C-4 
carboxyformimidoyl group yielded the C-4 free amine. The product was allowed to 
introduce the carboxyformimidoyl group into the C-4 amino function by the method 
of Umezawa, and subsequent removal of the dimedone protection to afford kasugamycin 
in 16% yield. 
   Reactions of dialkyl oxalodiimidates with amines have been reported to give 
oxalo-bis-amidines but not monosubstituted half oxalamidines in appreciable yields. 
We synthesized kasugamycin by the reaction of diethyl oxalodiimidate (56), which was 
prepared by a modified Houben method,55> with either free kasuganobiosamine or 
the corresponding salt by the method of Umezawa. In reaction of iminoesters with 
amines it has been observed that both the amines and their salts give the corresponding 
amidines and their salts.56, 
   The isolation of kasugamycin from the reaction mixture was very difficult because 
of its very low yield. Since kasuganobiosamine has two amino functions at C-2 and 
C-4 positions which are capable of reacting with the diiminoester and also since the 
diiminoester is reactive to give the oxalo-bis-amidines, the formation of by-products 
     CH3CH3 
---- 0\0 
      0 NH H2N0 NH H2N 
HO-C-C-NHHO-C-C-NH 
   00 
    OHOH OH     HO ----H0~QOH 
--- OH OHOH OH 
   5758 
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would exceed the one-to-one condensation of kasuganobiosamine and the diiminoester. 
Although kasugamycin was not isolated, it was identified with natural kasugamycin 
by means of bioautography with the growth inhibition against P. oryzae. 
   Similarly, kasugamycin analogs (57) and (58) were derived from (47) and (48), 
and (54) and (55), respectively. Diisopropylidene derivatives (38) and (39); (41) and 
(42); and (51) and (52) were also used as the starting material to introduce the carboxy-
formimidoyl group. The isopropylidene groups of the inositol moiety were removed 
simultaneously without any influence over the glycosidic linkages under the condition 
of mild acid hydrolysis of ethyl oxalodiimidyl into carboxyformimidoyl group. 
IV. Antifungal Test 
   In order to determine the biological activities of kasugamycin and its related 
compounds, the diffusion methods using such test microorganisms as P. oryzae and 
Pseudomonas fluorescens is used  frequently.") The use of P. oryzae is less accurate 
but more sensitive than the use of the latter. We measured the biological activities 
of the reaction products, (1), (57) and (58) without isolation using the paper disc method, 
one of the diffusion methods, using P. oryzae. The results are shown in Fig. 6, indicating 
that only kasugamycin was active but the other two analogs, L-chiro-inositol (57) and 
a//o-inositol (58) derivatives, were inactive. This suggests that D-chiro-inositol moiety 
is essential to the biological activity of kasugamycin.          
• 2
f b .. ss~K ` '* : r 
                                                                       F Fig. 6. Antitungal activities of autnentic KasugamycKasugamycin(lM) ana reaction mixtures atter introduction 
       of carboxyformimidoyl group, measured by the paper disc method with P. oryzae as an 
       indicator. The number in parentheses is that of the compound into which the carboxyfomimi-
       doyl group is introduced. 
      1. KSM 103ppm; 2. KSM 102 ppm; 3. KSM 10 ppm; 4. KSM 1 ppm; 
      5. KSM 10-1 ppm; 6. Blank; 7. (38); 8. (39); 9. (41); 10. (42); 11. (51); 12. (52); 
      13. (44); 14. (45); 15. (47); 16. (48); 17. (54); 18. (55). 
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                           EXPERIMENTAL 
   Melting points were uncorrected. IR spectra were recorded with a Shimadzu 
spectrophotometer AR 275. PMR spectra were recorded with a Varian A-60 or 
Hitachi R-20A spectrometer. Optical rotations were measured with a Yanagimoto 
photo-magnetic direct reading polarimeter, OR-20. 
Methyl 2-azido-4,6-O-benzylidene-2,3-dideoxy-a-D-arabino-hexopyranoside (6) 
   A solution of (9) (4.5 g) and sodium azide (2.2 g) in 90 % aqueous DMF(100 ml) 
was refluxed for 50 hrs. The reaction mixture was extracted with chloroform and 
evaporated to dryness. The residue was purified on a column of silicic acid with chloro-
form as eluant affording colorless syrup of (6) (2.25 g, 72 %) after usual procedures, 
[a]; +80° (c=1.0, CHC13), IR v ',1 cm-1: 2170(N3), 750 and 700 (monosubstituted 
benzene). 
Methyl 2-acetamido-4,6-O-benzylidene-2,3-dideoxy-a-D-arabino-hexopyranoside (7) 
   A solution of (6) (2.25 g) in methanol (50 ml) was hydrogenated over platinum 
black prepared from platinum oxide (230 mg) for 4 hrs. The catalyst was removed by 
filtration and the filtrate was evaporated in vacuo. The residual solid was acetylated 
with acetic anhydride (1.5 ml) in methanol. The solution was poured into ice-water 
and extracted with chloroform. The extract was washed with 2N-HCI, 2N-Na2CO3 
and water successively, and dried over Na2SO4. Evaporation of chloroform gave a 
syrup, which was crystallized from ethyl acetate-hexane to give colorless needles of 
(7) (2.2 g, 78 %), mp 174.5-175.5, [a];; +73.1 ° (c=1.0, CHCI3). Anal, Found: C, 
62.76; H, 7.00; N, 4.73. Calcd. for CI6H2105N: C, 62.52; H, 6.88; N, 4.56%. IR 
vNuiol cm-1: 3350 (NH), 1650 and 1560 (NH-C=0), 750 and 700 (monosubstituted 
benzene). PMR (in CDC13) z: 7.96 (3H, s., CH3-CONH), 6.60 (3H, s., CH3O), 5.48 
(I H, d., J1,2=0.8 Hz, H1). 
Methyl 4,6-O-benzylidene-3-deoxy-a-D-erythro-hezopyranosid-2-ulose (11) 
   To a solution of (8) (1 g) in DMSO (30 ml), were added DCCD (3.5 g) and 
pyridinium trifluoroacetate (340 mg). After standing at room temperature for 5 days, 
the precipitated crystals were removed by filtration. The filtrate was poured into 
icewater and left at room temperature for 3 hrs. After removal of the precipitated 
solid by filtration, the filtrate was extracted with chloroform, which was then evaporated 
in vacuo. The resulting residue was extracted with hot hexane, which was left at room 
temperature to give colorless needles of (11) (78 mg, 78 %), mp 114-115°, [a]; +101° 
(c=0.3, CHC13). Anal. Found: C, 63.73; H, 6.22, Calcd. for C14H1605: C, 63.62; H, 
6.10 %. IR v nix°I cm-I : 1730 (C=0), 760 and 710 (monosubstituted benzene). 
Methyl 4,6-O-benzylidene-2,3-dideoxy-2-oximino-a-n-erythro-hexopyranoside (12) 
   To a solution of hydroxylamine hydrochloride (1.8 g) in water (10 ml) previously 
adjusted to pH 4 by sodium acetate was added a solution of (11) (2.25 g) in 80% aqueous 
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methanol solution (125  ml). The temperature was kept at 0°C and sodium acetate 
was added with stirring so as to keep the solution at pH 4. After the addition was 
complete, the reaction mixture was stirred for 4 hrs. at room temperature. As the 
reaction proceeded, colorless crystals began to precipitate. The solution was adjusted 
to pH 7 with 2N-Na2CO3 and recrystallized from ethanol giving colorless crystals of 
(12) (2.6 g, 98%), mp 150-157°C, [a]D +84.4° (c=0.5, CHC13), Anal. Found: C, 
60.05; H, 6.27; N, 5.25. Calcd. for C14H17O5N: C, 60.20; H, 6.14; N, 5.02. PMR (in 
CDC13) r: 6.58 (3H, s., CH3O), 5.09 (1H, s., 1H), 6.47 (1H, s., ph-CH). 
LiAlH4 reduction of (12) 
   A solution of (12) (500 mg) in dry ether (50 ml) was added dropwise with stirring 
to a cold suspension of LiA1H4 (250 mg) in dry ether (40 ml). After the addition was 
complete, the reaction mixture was refluxed for 4 hrs. Excess of LiA1H4 was 
decomposed with water and the precipitate was removed by filtration. The filtrate 
was evaporated in vacuo giving a solid which was acetylated with acetic anhydride 
in pyridine. After addition of ice-water the solution was extracted with chloroform, 
and the chloroform solution was washed with 2N-HCI, 2N-Na2CO3 and water 
successively and dried over Na2SO4. The solvent was evaporated to give a colorless 
solid. Recrystallization from ethyl acetate gave crystals of (10) (670 mg), mp 224 
(sublime), [a]j; +53.7° (c=1.0, CHC13), Anal. Found: C, 62.58; H, 6.89; N, 4.52. 
Calcd. for C16H21O5N: C, 62.52; H, 6.88; N, 4.56%. IR ya,uV cm-': 3300 (NH), 1650 
and 1560 (NH-C=0), 750 and 700 (monosubstituted benzene), PMR (in CDCI3) r: 
8.03 (3H, s., CH3-CONH), 6.59 (3H, s., CH3-O), 5.40 (1H, d., J,,2=3.5 Hz). The 
mother liquor was evaporated to dryness and the resulting syrup was purified on a 
silicic acid column with CHCI3: ethyl acetate (1:1, V/V) to afford further crop of 
crystals of (10) (130 mg, total yield: 73%), and colorless needles of (7) (160 mg, 15%). 
Methyl 2-acetamido-2,3-dideoxy-a-D-arabino-hexopyranoside (13) and its acetate 
   A suspension of (7) (1.5 g) in aqueous sulfuric acid (30 ml) adjusted to pH 2 was 
warmed at 60-70°C with occasional shaking for 3 hrs. The reaction mixture was 
washed with chloroform to remove benzaldehyde. The aqueous layer was neutralized 
with Amberlite IR-45 (OH- form) and the resin was removed by filtration. The filtrate 
was evaporated in vacuo to give a colorless syrup (1.1 g) of (13). The syrup was 
acetylated with pyridine and acetic anhydride and poured into ice-water and then 
extracted with chloroform. After washing with 2N-HCI, 2N-Na2CO3 and water suc-
cessively. Evaporation of the solvent gave crystalline solids, which was recrystallized 
from ethyl acetate to give colorless needles of the acetate of (13) (1.5 g, quantitative 
yield), mp 125-126°C, [a]„ +67.3° (c=1.0, CHC13), Anal. Found: C, 51.54; H, 
7.04; N, 4.38. Calcd. for C13H21O7N: C, 51.48; H, 6.98; N, 4.62%. IR vm"ao1 cm-': 
3320 (NH), 1740 (O-C=0), 1650 and 1540 (NH-C=0). 
Methyl 2-acetamido-4-O-acety1-2,3-dideoxy-6-O p-tolylsulfonyl-a-v-arabino— 
hexopyranoside (18) 
   To a solution of (13) (1.78 g) in dry pyridine (15 nil) was added p-toluene sulfonyl 
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chloride (1.86 g) in dry pyridine (15 ml) dropwise with stirring at —5°C in 1 hr. After 
the addition was complete, the solution was further stirred at —5-0°C for 3 hrs., and 
stood in a refrigerator (5°C) for 30 hrs. and then at 30° for 20 hrs. Acetic anhydride 
(5 ml) was added to the reaction mixture and the solution was allowed to stand at room 
temperature over night. Cold water was added to the solution and extracted with 
chloroform. After washing with 2N-HC1, 2N-Na2CO3 and water successively and 
drying over Na2SO4i the solvent was evaporated to a brown oil. The oil was triturated 
in ethyl acetate-hexane to afford crystalline prisms of (18) (330 mg, 56.7 %), mp 138-
141 °, [a]ll +71.3° (c=1.0, CHC13). Anal. Found: C, 51.82; H, 6.34; N, 3.45. Calcd. 
for CI8H2508NS: C, 52.03; H, 6.07; N, 3.38 %. IR pmax cm-1 : 3450 (NH), 1750, 1685 
and 1520 (NH-C=0), 1320 and 1350 (OS02, asym.), 1195 and 1185 (OS02, sym.). 
Methyl 2-acetamido-4-O-acetyl-6-iodo-2,3,6-trideoxy-a-n-arabino-hexopyranoside (19) 
   A solution of (18) (1.4 g) and sodium iodide (2.0 g) in absolute acetone was heated 
at 100 °C in a sealed tube for 10 hrs. After cooling, crystals of sodium p-toluenesulfonate 
were removed by filtration. The filtrate was evaporated to dryness and the oily residue 
was shaken with water and chloroform. The chloroform layer was washed with 10 %-
NaHS03 and water. After drying over Na2SO4 and evaporating to dryness, a slightly 
yellow oil of (19) (1.3 g) was obtained, which showed a single spot on silica gel thin 
layer chromatogram (developing solvent: ethyl acetate). IR y;aX cm* 3300 (NH), 
1735 (O-C=0), 1665 and 1550 (NH-C=0). 
Methyl 2-acetamido-2,3,6-trideoxy-a-D-ara bino-hexopyranoside (20) 
   To a solution of (19) (1.63 g) in methanol (50 ml) were added Raney Ni W-2 
(5 g) and Amberlite IR-45 (2 g). The mixture was shaken under hydrogen gas for 
2 hrs. The catalyst and the resine were filtered off, and the filtrate was evaporated to 
give a colorless syrup. After treatment with sodium methoxide in methanol, the solution 
was neutralized with Amberlite IR-120 (H+ form). Resin was removed by filtration, 
and then the filtrate was evaporated to give a syrup, which was triturated with ethyl 
acetate-hexane to yield (20) as colorless needles (680 mg, quantitative), mp 149-150°, 
[a];° +64.4° (c=1.0, EtOH). Anal. Found: C, 53.06; H, 8.36; N, 6.91. Calcd. for 
C9H„04N: C, 53.19; H, 8.43; N, 6.89 %. IR U'm1,1 cm-1: 3420 (OH), 3340 (NH), 1650 
and 1540 (NH-C=0). 
Methyl 2-acetamido-2,3,6-trideoxy-a-D-threo-hexopyranosid-4-ulose (25) 
   To a solution of (20) (790 mg) in absolute acetone (15 ml) was added an aqueous 
acidic solution of chromic acid (Cr03: H2SO4: H2O=2.7 g: 2 ml: 8 ml) (2.5 ml) dropwise 
with stirring at room temperature. After addition of methanol (1 ml) to the solution 
to decompose an excess of chromic acid, the supernatant was separated by decantation. 
The residue was extracted with hot acetone. The supernatant and the acetone extract 
were combined together and neutralized with Amberlite 1R-45. After removal of the 
resin, the solution was evaporated and the residual oil was shaken with chloroform 
and water. The chloroform solution was dried over Na2SO4. The solution was evapo-
rated to dryness and recrystallized from ethyl acetatehexane to yield colorless needles 
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of (25) (500 mg,  63%), mp 125-126°, [a]; +148° (c=0.5, CHCI3). Anal. Found: 
C, 53.91; 11, 7.81; N, 6.99. Calcd. for C9H15O4N: C, 53.72; H, 7.51; N, 6.96%. IR 
vm;,x cm-1: 3270 (NH), 1730 (C—C=0), 1650 and 1550 (NH—C=0). 
Methyl 2-acetamido-2,3,6-trideoxy-a-n-/yxo-hexopyranoside (22) 
   A solution of (25) (1.2 g) in methanol (100 ml) was shaken with hydrogen gas in 
the presence of platinum oxide (120 mg) at room temperature for 15 hrs. The catalyst 
was removed and the solution evaporated to dryness. The resulting syrup (1.1 g) was 
chromatographed on a column of silicic acid (33 g). From the faster developed fractions 
with chloroform-methanol (50: 1 V/V) colorless needles of (22) (685 mg, 57 %) were 
obtained, mp 121-122.5°, [a]D —16° (c=1.0, EtOH). Anal. Found: C, 53.35; H, 
8.55; N, 6.79. Calcd. for C$H17O4N: C, 53.19; H, 8.43; N, 6.89%. IR vmAx cm-1: 
3430 (OH), 3360 (NH), 1660 and 1530 (NH—C=0). From the slower developed 
fractions, crystals of (20) (340 mg, 20%) were obtained. 
Methyl 2-acetamido-4-O-methylsulfonyl-2,3,6-trideoxy-a-D-lyxo-hexopyranoside (23) 
   Methanesulfonyl chloride (0.75 ml) was added dropwise at —10- —5°C with 
stirring to a solution of (22) (650 mg) in pyridine (15 ml). Stirring was continued for 
3 hrs. at 0°C and for 5 hrs. at room temperature. Ice-water was added to the solution 
and extracted with chloroform. Evaporation of the chloroform gave a brown oil 
which was purified on a silicic acid column to yield (23) as a slightly yellow syrup 
(460 mg, 51 %). The syrup showed a single spot on silica gel thin layer chromatogram 
(developing solvent; ethyl acetate). [ar +6.8° (c=1.2, CHCI3). 1R vn,'cm 1: 
3400 (NH, s., broad), 1670 and 1520 (NH—C=0), 1200 and 1180 (OSO2). 
Methyl 2,4-diacetamido-2,3,4,6-tetradeoxy-a-D-arabino-hexopyranoside (21) 
   A suspension of (23) (460 mg) and sodium azide (400 mg) in DMF (10 ml) was 
refluxed for 6 hrs. The solution was evaporated to dryness. The resulting syrup was 
extracted with chloroform which was washed with water. After drying over Na2SO4i 
the solvent was evaporated in vacuo to give a brown syrup of the corresponding azide 
(280 mg), which was dissolved in methanol (15 ml) and shaken with hydrogen gas for 
3 hrs. in the presence of platinum oxide (30 mg). After removal of the catalyst, the 
solution was acetylated with acetic anhydride (0.5 ml). The solution was evaporated 
and the resulting brown syrup was purified on a column of silicic acid (10 g) with 
chloroform-methanol (50:1-30:1 V/V) to give crystalline solids. Recrystallization 
from ethyl acetate afforded colorless needles of (21) (63 mg, yield from (23); 16%), 
mp 194.5-196°, [a]n -(-100° (c=1.0, H2O). Anal. Found: C, 54.22; H, 8.39; N, 11.57. 
Calcd. for C11H2004N2: C, 54.08; H, 8.25; N, 11.47%. IR vmBx cm-1: 3300 (NH), 
1650 and 1560 (NH—C=0). PMR (in D2O) r: 8.81 (3H, d., J5,6=6.0 Hz, CH3-5C), 
8.02 (3H, s., CH3-CONH), 7.97 (3H, s., CI-13-CONH), 6.58 (3H, s., CH3-O), 5.40 
(1H, d., J1,2=1.5 Hz, 1H). 
Methyl 2-acetamido-4-oximino-2,3,4,6-tetradeoxy-a-D-threo-hexopyranoside (26) 
   To a solution of (25) (300 mg) and hydroxylamine hydrochloride (380 mg) in 50% 
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aqueous methanol (6 ml) was added sodium acetate so as to keep the solution at pH 4. 
After the addition was complete, the stirring was continued for 5 hrs. at room temper-
ature. The pH of the solution was adjusted to 7 by 2N-Na2CO3 and extracted with 
chloroform. After washing with water and drying over Na2SO4, the solvent was distilled 
off, and the residual solid was recrystallized from ethyl acetate to afford (26) as colorless 
needles (285 mg, 69 %), mp 155-159°, [a]ll +67° (c=1.0, CHCI3). Anal. Found: 
C, 50.22; H, 7.64; N, 12.67. Calcd. for C9H1604N2: C, 49.99; H, 7.46; N, 12.96%. 
IR v; cm-1: 3313 (NH), 1660 and 1570 (NH—C=0). 
Methyl 2,4-diacetamido-2,3,4,6-tetradeoxy-a-D-lyxo-hexopyranoside (24) 
   A solution of (26) (70 mg) in acetic acid (15 ml) was shaken with hydrogen gas 
in the presence of platinum oxide (10 mg) at room temperature for 3 hrs. The catalyst 
was filtered off and the filtrate was evaporated. The residual oil was acetylated with 
acetic anhydride (0.2 ml) in methanol. The solution was evaporated and the resulting 
syrup was triturated with ethyl acetate giving colorless needles of (24) (85 mg, 93 %), 
mp 218-220°, [a]) +20° (c=1.0, CHC13). Anal. Found: C, 54.25; H, 8.33; N, 11.29. 
Calcd. for C11H2004N2: C, 54.08; H, 8.25; N, 11.47%. IR vmaX cm-1: 3320 (NH), 
1685, 1630 and 1535 (NH—C=0), PMR (in D20) r: 8.83 (3H, d., J1,2=7.0 Hz, 
CH3-5C), 8.00 (3H, s., CH3-CONH), 7.97 (3H, s., CH3-CONH), 6.58 (3H, s., CH3-O) 
and 5.31 (1H, d., J1,2=2.8 Hz, 1H). 
2,4-Diacetamido-1- O-acetyl-2,3,4,6-tetradcoxy-D-a ra bino-hexopyranose(Triacetyl 
kasugamine) (27) 
   (21) (20 mg) was treated with 5N-formic acid (5 ml) at 95°C for 15 min. The 
solution was evaporated and acetylated with pyridine and acetic anhydride. After 
evaporation of the solvent, a syrup was chromatographed on the column of silicic 
acid with CHC13: McOH (50:1 V/V) to afford a colorless syrup of (27) (90 mg, 40 %) 
and the unaltered starting material (21) (50 mg, 30%). IR vm`aX cm-1: 1710 (0—C=0), 
1630 and 1540 (NH—C=0). 
2,4-Diacetamido-l-chloro-2,3,4,6-tetradcoxy-a-D-a ra bi no-hexopyranose 
(Acetochloro-kasugamine) (28) 
   (27) dried over phosphorous pentoxide was dissolved in anhydrous chloroform 
(15 ml) and hydrochloric acid saturated acetic acid (15 ml) in a round bottom flask 
with a stopper. The solution was allowed to stand at 30°C with occasional violent 
shaking for 24 hrs. The supernatant was decanted off. The resulting solid was washed 
with anhydrous ether 5 times cautiously in preventing moisture. Desiccation over 
pottasium hydroxide to afford (28) as an amorphous solid (310 mg, 87 %), which was 
too hygroscopic to be recrystallized. It was used for the next reaction without 
purification. 
DL-chiro-inositol 
a. From cis-benzeneglycol (30) 
   To a solution of tetraacetate of conduritol-F (32), derived from cis-benzeneglycol 
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via 1,2-anhydro-conduritol-E, in a mixture of dioxane (200 ml) and water (100 ml) 
was added a solution of  KMnO4 (2.75 g) in water (200 ml) dropwise with vigorous 
stirring at 0-10°C. After the addition was complete, the solution was filtered. The 
filtrate was extracted with methylene chloride. The organic layer was evaporated 
in vacuo to give a syrup, which was acetylated with acetic anhydride (15 ml) in pyridine 
(15 ml). The solution was poured into ice-water and extracted with ethylene chloride, 
which was then washed with 2N-HCI, 2N-Na2CO3 and water successively. After drying 
over Na2SO4i ethylene chloride was evaporated in vacuo to give a colorless syrup (6.5 
g), which was deacetylated with sodium methoxide in methanol. The resulting crystals 
of (33) were gathered by filtration (3.3 g, 58 %), mp 253°. 
b. From myo-inositol 
   Commercially available myo-inositol (10 g) was suspended in acetic acid-sulfuric 
acid-water (190:3:7, V/V) (1,000 ml) and refluxed for 12 days. The brown reaction 
mixture was concentrated in vacuo to 50 ml. Acetic anhydride (100 ml) was added 
under cooling and left at room temperature over night. From the solution, when 
poured into ice-water (400 ml), hexa-O-acetyl-myo-inositol was precipitated. After the 
removal of the precipitate by filtration, the filtrate was extracted with ether. Evaporation 
of the solvent gave a syrup, which was treated with sodium methoxide in methanol 
to give precipitates. Filtration and washing with methanol afford the colorless crystals 
of (33) (4.5 g, 45 %). 
1,2 ;3,4 ;5,6-Tri-O-isopropylidene-DL-chiro-inositol (34) 
   (32) (2.7 g) and p-toluenesulfonic acid (400 mg) was suspended in DMF (50 ml) 
and 2,2-dimethoxypropane (35 ml) and allowed to stand at 80°C for 10 hrs. with 
stirring. After neutralization with Amberlite IRA-410, the resin was removed by 
filtration. The filtrate was evaporated in vacuo. Water was added and evaporated to 
yield crude crystals, which were extracted with chloroform. Evaporation of chloroform 
gave colorless crystals of (34) (3.3 g, 71 %). Recrystallization from ethyl acetate afforded 
analytical sample, mp 135-156°, IR vma'x 1 cm': 880 and 860 (isopropylidene). Anal. 
Found: C, 59.94; H, 8.32, Calcd. for C15H2406: C, 59.98; H, 8.32%. 
1,2;5,6-Di-O-isopropylidene-DL-chiro-inositol (35) 
   (33) was dissolved in a mixed solvent (chloroform: acetic acid: water=12: 14:4 
V/V) and stirred for 15 hrs. at 30-40°C. From the reaction mixture DL-chiro-inositol 
was removed by filtration, and the filtrate was evaporated to dryness. The residual 
syrup was extracted with chloroform, which, after evaporation, gave crude crystals of 
(34). Recrystallization gave colorless needles (2.0 g, 71 %), mp 161-162°. Anal. Found: 
C, 55.44; H, 7.78, Calcd. for C,2H2006: C, 55.37; H, 7.75 %. IR vmQy°' cm-1: 3280 
(OH), 880 and 860 (isopropylidene). 
D-1,2;5,6-Di-O-isopropylidene-3-O-(2,4-diacetamido-2,3,4,6-tetradeoxy-a-D-a rabino— 
hexopyranosyl)-cliiro-inositol (36) 
   (43) (12 g) was treated with sodium methoxide in methanol. The solution was 
neutralized with Amberlite IR-120 and evaporated. The residual syrup and p— 
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toluenesulfonic acid (100 mg) were dissolved in a mixture of DMF (54 ml) and 2,2-
dimethoxypropane (18 ml), and warmed at 60°C for 15 hrs. Treatment with Amberlite 
IRA-410, subsequent removal of the resine and evaporation of the filtrate gave crude 
crystals. Recrystallization from ethyl acetate-hexane afforded (36) as colorless needles 
(4.8 g, 51%), mp 156-160°, [a];; +62° (c=2.0, CHCI3), Anal. Found: C, 54.10; 
H, 7.90; N, 5.80. Calcd. for C22H3609.H20: C, 53.86; H, 7.81; N, 5.71 %. IR vr,'?°' cm-' : 
3400 (NH), 1680, 1640 and 1570 (NH—C=0), 880 and 860 (isopropylidene). PMR 
(in CDC13) z-: 8.82 (3H, d., J5,6=5.0 Hz), 8.64 and 8.50 (6H each, s., isopropylidene), 
8.00 (6H, s., CH3-CONH), 4.98 (1H, d., J,,2=1.4 Hz, 'H). 
Condensation Reaction 
   (35) (1.3 g) was dissolved in anhydrous chloroform (100 ml). To the solution, 
silver carbonate (4.2 g), silver perchlorate (500 mg) and drierite (14 g) were added and 
stirred for 10 hrs. in dark under anhydrous condition. Then, (28) (3 g) was added by 
portions with stirring. After the addition was complete, the stirring was continued 
for 6 days at 25-30°C. Water (1 ml) was added to the reaction mixture and stirred for 
an hour. Insoluble materials were filtered off on Celite 545 pad, and washed with 
chloroform. Decolorization and the following evaporation of the fitrate and 
purification on a column of silicic acid (60 g) yielded the condensed product as a syrup 
(500 mg, 22%), which was fractionated carefully by column chromatography over 
silicic acid (15 g). Chloroform-methanol (40:1-20:1 V/V) was used as eluent. The 
first fractions gave a syrup (120 mg), which was crystallized from ethyl acetatehexane 
to afford crystals of (36) (70 mg). Repeated chromatography gave the second fractions 
as a pure state (97 mg), whose structure was confirmed to be L-1,2;5,6-di-O-isopropy-
] i dene-3-O-(2,4-diacetamid o-2, 3,4, 6-tetradeoxy-a-D-arabino-hexopyranosyl)-chil•o-
inositol (40). The purity of each fraction was checked by means of gas chromatography 
of their TMS derivatives as described later. 
   (40); [at -I-52° (c=2.0, CHCI3). IR vm°; cm-': 1640 and 1540 (NH—C=0), 
PMR (in CDC13) r: 8.80 (3H, d., J5,6= .0 1-Iz, CH3-5C), 8.66 and 8.50 (6H each, s., 
isopropylidene), 8.03 and 7.98 (3H each, s., CH3-CONH), 6.93 (IH, d., J,,2=1.4 Hz, 
H) 
Preparation of analytical samples for GLC 
   (36) (2 mg) was dissolved in anhydrous pyridine. To the solution, bis-trimethylsilyl 
formamide (0.02 ml) was added, and refluxed for an hour at 140°C. The reaction 
mixture was cooled and allowed for gas chromatographic analysis Column: 5% OV-17 
on chromosorb-W 60/80 (3 mm x 750 mm s.^); Temp., 260°C; Carrier gas, He(20 
nil/min.); Detector, FID. The corresponding analytical samples were prepared from 
(40) and condensation product. 
D-1,2 ;5,6-Di- 0-isopropylidene-4- O-m ethylsulfonyl-3- O-(2,4-dia m ino-2,3,4,6-tetradeoxy-
a-D-arabino-hexopyranosyl)-chiro-inositol (37) 
   To the solution of (36) (4 g) in anhydrous pyridine (50 ml), methanesulfonyl 
chloride was added dropwise with stirring at —5 —0°C. After the addition was over, 
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the stirring was continued for 3 hrs. at 0°C and then 2 days at the room temperature. 
After the addition of ice water (50 ml), the reaction mixture was extracted with chloro-
form. The chloroform layer was washed with 2N-HCI,  2N-Na2CO3 and sat.-NaCI 
successively and dried over Na2SO4. Evaporation of the solvent gave a brown colored 
syrup (2.2 g) which was purified on silicic acid column (60 g) by elution with chloroform-
methanol (30:1 V/V) to obtain (37) as a pale yellow syrup (1.1 g, 24%), [a]U +88.5° 
(c=2.0, CHCI3). IR vircm-1: 8.82 (3H, d., J5,6=5.5 Hz, CH3-5C), 8.68 (61-1, s., 
isopropylidene), 8.65 and 8.44 (3H each, s., isopropylidene), 8.00 (6H, s., 2CH3-CONH), 
6.80 (3H, s., CH3-S03), 5.05 (1H, doublet, J,,2=2.1 Hz, 'H). 
D-3- O-Acetyl-1,2 ;5,6-di- 0-isopropylidene-4- O-(2,4-diacetamido-2,3,4,6-tetradeo xy-a-D-
arabino-hexopyranosyl)-allo-inositol (49) and D-1,2;5,6-di-O-isopropylidene-4-(2,4-
diacetamido-2,3,4,6-tetradeoxy-a-o-arabino-hexopyranosyl)-allo-inositol (50) 
   (37) (200 mg) and sodium acetate (70 mg) was dissolved in DMF (10 ml) contain-
ing 0.5% of water and refluxed for 70 hrs. After removal of insoluble solids 
by filtration, the filtrate was evaporated in vacuo to give a brown syrup (170 tng), which 
was purified on the column of silicic acid (8 g). By elution with chloroform-methanol. 
(40:1 V/V), a syrup of (49) (50 mg, 26.4%) was obtained from the first fractions, and 
a colorless needle of (50) (85 mg, 49.5%) from the second fractions. (49) ; [a]7; +83.5° 
(c=2.0, CHCI3), IR v2Zt cm-': 3280 (NH), 1740 (O—C=0), 1650 and 1540 (NH— 
C=0), PMR (in CDCI3) r: 8.81 (3H, d., J5,6=6.6 Hz, CH3-5C), 8.66, 8.62, 8.55 and 
8.52 (3H each, s., isopropylidene), 8.02, 7.99 and 7.90 (3H each, s., CH3-CO), 5.22 
(1H, d., J,,2=1.5 Hz). 
(50); [a]D +50.5 (c=2.0, CHCI3), mp 234-237°, PMR (in CDCI3) r: 8.83 (3H, d., 
J5,6=5.4 Hz, CH3-5C), 9.64 (6H, s., isopropylidene), 8.53 and 8.47 (3H each, s., iso-
propylidene), 8.00 and 7.82 (3H each, s., CH3-CO), 5.20 (1H, doublet, J1,2=0.1 Hz, 
1H). Anal. Found: C, 55.65; H, 7.62; N, 5.84, Calcd. for C22H3609N2: C, 55.92; H, 
7.68; N, 5.93 %. 
D and L-1,2,4,5,6-Penta-O-acetyl-3-O-(2,4-diacetamido-2,3,4,6-tetradeoxy-a-D-
arabino-hexopyranosyl)-chiro-inositol (43), (46) and L-2,3,4,6-penta-O-acetyl-1-O-
(2,4-diacetamido-2,3,4,6-tetradeoxy-a-D-a rabbi o-hexopyranosyl)-allo-inositol (53) 
   The solution of (36) (125 mg) in 50% aqueous acetic acid (4 ml) was warmed at 
70-80°C for 3 hrs. The solution was evaporated to dryness and the resulting syrup 
was acetylated with pyridine (3 ml) and acetic anhydride (3 ml). The reaction was 
stopped by the addition of methanol. Evaporation of the solvent to give a syrup which 
was crystallized from ethyl acetatehexane to yield colorless crystals of (43) (120 mg, 
75%), mp 248-252°, [at' +34.5° (c=1.0, EtOH). IR n'X` cm-': 3270 (NH), 1750 
(O—C=0), 1670 (shoulder), 1645 and 1570 (NH—C=0), PMR (in CDCI3) r: 8.80 
(3H, d., J5,6=5.8 Hz, CH3-5C), 8.01 (6H, s., CH3-C=O), 7.98, 7.95, 7.91, 7.85 and 
7.48 (3H each, s., CH3-C=0), 5.19 (111, d., J1,2=1.0 Hz, 'H). 
   According to the same procedure, (46) and (53) were obtained from (40) and (50) 
respectively. 
   (46); [a]ll +36° (c=1.0, CHCI3), IR v1= cm-': 1755 (O—C=0), 1550 and 
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1550 (NH—C=0), PMR (in CDCI3) z-: 8.87 (3H, d., J5,6=6.0 Hz, CH3-5C), 8.01 
(6H, s., CH3-CO), 8.04, 7.92, 7.89, 7.84 and 7.82 (3H each, s., CH3-CO), 5.29 (1H, 
d., J1,2=1.7 Hz). 
   (53); [a]D +83.5° (c=2.0, CHC13), IR vmB'_ cm-1: 1730 (0—C=O), 1640 and 
1540 (NH--C=O), PMR (in CDC13) r: 8.80 (3H, d., J5,6=5.5 Hz, CH3-5C) 8.00 and 
7.85 (6H each, s., CH3-CO), 7.98, 7.96 and 7.92 (3H each, s., CH3-00), 5.22 (1H, d., 
J1,2=1.3 Hz, 1H). 
D and L-1,2;5,6-Di-O-isopropylidene-3-O-(2,4-diamino-2,3,4,6-tetradeoxy-a-D-arabino-
hexopyranosyl-chiro-inositol (38), (41) and corresponding hydrochloride (39), (42). 
D-1,2 ;5, 6-di-O-isopropylidene-4- O-(2,4-diamino-2,3,4,6-tetradeoxy-a-D-a rabino-
hexopyranosyl)-allo-inositol (51) and its hydrochloride (52) 
   The solution of (36) (6.3 g) in saturated aqueous barium hydroxide (80 ml) was 
refluxed for 3 days. After cooling, the precipitate was filtered off and the filtrate was 
concentrated to 20 nil. Ethanol (20 ml) was added and the resulting precipitate was 
removed by filtration. The filtrate was neutralized with 6N-sulfuric acid, and the 
precipitated barium sulfate was removed by centrifugation (6000 rpm. 15 min.). The 
supernatant was decolorized with active carbon and then evaporated in vacuo. The 
resulting syrup was dissolved in methanol and made alkaline Amberlite IRA-410. 
After the removal of the resin, the solution was concentrated to give an amorphous solid 
(3.2 g, 62%) of (38). [a]D +93 °(C=1.0, H20), IR v! cm-1: 1610 (NH2, broad), 880 
860 (isopropylidene). (38) (3.2 g) was dissolved in water (20 ml) and neutralized with 
and 0.5N-HC1. Evaporation gave crude crystals, which was recrystallized from ethanol 
to give colorless crystals of (39) (2.4 g, 63 %), mp 240-243° (decomp.), [a]p +46.8 
(c=1.9, H/0), .IR vmax°' cm-1: 1590 (N +H3), 1520 (NH), 880 and 870 (isopropylidene). 
Similarly, (41), [a]U' +46.8° (c=1.9, H20), and (42), [ar +33° (c=2.0, H20), from 
(40), and (51), [al +102°  (c=1.0, H2O) and (52), [a];a +53° (c=2.0, H2O) from 
(50) were obtained. 
D and L-3-O-(2,4-Diamino-2,3,4,6-tetradeoxy-a-D-arabino-hexopyranosyl)-chiro-
inositol (44), (47) and their corresponding hydrochloride (45), (48). 
L-1-O-(2,4-diamino-2,3,4,6-tetradeoxy-a-D-arabino-hexopyranosyl)-allo-inositol (54) 
and its hydrochloride (55) 
   (43) (4 g) was dissolved in saturated aqueous barium hydroxide. The solution was 
refluxed for 20 hrs. and worked up as described above to give the hydrochloride (45) 
(2 g, 57.3%) as crystals, mp 225-230° (dec), [a]l; +103°  (c=1.8, H20), IR ;at'  cm-1: 
3380 (OH broad), 1615 (N+H3), 1520 (NH). Anal. Found: C, 36.10; H, 7.70. Calcd. 
for C,2H2407N2•H20.2HCI: C, 36.23; H, 6.88%. 
(45) was dissolved in water (10 ml) and made alkaline by Amberlite IRA-410. The 
resine was removed by filtration and the filtrate was evaporated in vacuo to yield (44) 
as an amorphous solid. By means of the same procedures, (47) and (48), and (54) and 
(55) were derived from (46) and (53) respectively. 
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Hydrolysis of (41) 
   (41) (70 mg) was dissolved in 6N-HC1 (5 ml) and heated at 100°C for an hour. 
The solvent was evaporated in vacuo. The resulting syrup was acetylated with pyridine 
(1 ml) and anhydrous acetic acid (1  ml). After addition of water, the solution was 
extracted with chloroform followed by successive washing with 2N-HCI, 2N-Na2CO3 
and sat.-NaCl. The syrup (40 mg) obtained by evaporation of chloroform was purified 
on the column of silicic acid (1.5 g) to give crystals, which were recrystallized from 
ethanol to give colorless prisms (28 mg, 56%), mp 96-98°, [at' —0.5° (c=1.0, CHC13). 
By deacetylation of the acetate with sodium methoxide in methanol, L-chiro-inositol 
was obtained. mp 246-248°, [a]D —64.3° (c=2.0, H2O), lit., mp 247°, [a]ll' —65°. 
Hydrolysis of (50) 
   (50) (34 mg) was dissolved in 6N-HC1 (1 ml) and warmed at 50°C for 3 hrs. The 
solvent was evaporated to give a syrup. Acetylation, extraction and column chro-
matography as described above gave a syrup, which was crystallized from ethanol 
yields hexa-O-acetyl-a//o-inositol as colorless prisms (30 mg, 96%), mp 138-141°, 
lit., nip 141-142°. 
Diethyl oxalodiimidate (56) 
   Sodium cyanide (22.5 g) was dissolved in a mixture of water (100 ml) and ethanol 
(66 ml). Cl2 was bubbled into the solution at —10— —20°C. After about 90 minutes, 
oily product was separated. The bubbling was stopped at a pH point of weak alkaline 
or neutral. The reaction mixture was extracted with ether, which was washed two 
times with water and dried over Na2SO4. The solvent was evaporated and the resulting 
brown syrup was purified by fractional distillation. The fraction distilled at 65-70°C 
(18 mmHg) was redistilled to give a colorless syrup. Crystallization from ether yielded 
a colorless needle (2.5 g), bpis 69°, mp 21.5-22°. IR vll13rL' cm-': 3200 (NH), 
1620 (NH=C). 
Preparation of materials for bioassay 
   (38), (39), (44) and (45) (derivatives of D-chiro-inositol), (41), (42), (47) and (48) 
(derivatives of L-chiro-inositol), and (51), (52), (54) and (55) (derivatives of al/o-inositol) 
(3-5 mg, each) were dissolved in a mixture of 50% aqueous ethanol (3 ml to 0.1 mM 
of the sample) and ethyl diiminooxalate (1.2 molar equivelent to the sample). The 
solution was left for 10 hrs. at room temperature and then the solution was evaporated 
to dryness as rapidly as possible. To the resulting syrup, 0.1N-hydrochloric acid (3.5 
ml to 0.01 mM of the starting material) was added and the solution was warmed at 
50°C for 2 hrs., which was used for the bioassay. 
Antifungal test 
Miroorganism: Piricularia oryzae 
Medium 
   (i) Czapeck's-rice straw extract medium: Rice straw (100 g) was boiled in water 
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(1,000 ml) for 30 min. and filtered through cloth. To the filtrate, MgSO4 (0.5 g), 
K2HPO4 (1.0 g), KC1 (0.5 g), NaNO3 (2.0 g), FeSO4 (0.01 g), sucrose (30 g) and agar 
(15 g) were added. 
   (ii) Sucrose-rice straw extract medium: To the rice straw extract (1,000 ml) prepared 
as described above, sucrose (15 g) was added. 
   Preparation of plates for bioassay 
   (i) Spola suspension: P. oryzae was cultured on a Czapec's-rice straw extract 
medium slant at 30°C. After 10 clays, the spola was suspended in a sterililized water 
(10 ml) and filtered through clothe. 
   (ii) Basal layer: 1.5% Agar solution (250 ml) was plated in a alminum box 
(35.5 x 20.5 x 5 cm3). On this layer, a glass plate (35 x 20 x 0.1 cm3) was settled. 
   (iii) Seed layer: The spola suspension (2 ml) was added to the mixture of sucrose— 
rice straw extract medium (75 ml) and citrate-phosphate buffer (pH 5, 75 ml) containing 
0.8 % agar. The mixture was plated on the basal layer. 
   (iv) Bioassay: Assay was performed by paper disc (d=0.64 mm) method. 
Inhibition zone was measured after 70 hrs. incubation at 30°C. The result is shown 
in Fig. 6. 
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